消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第1頁
消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第2頁
消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第3頁
消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第4頁
消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究_第5頁
已閱讀5頁,還剩4頁未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病的臨床研究摘要:

目的:探討消癥散積Ⅰ號方治療濕郁血瘀型非酒精性脂肪性肝病(NAFLD)的臨床療效和安全性。

方法:選擇2017年1月至2019年12月在我院住院治療的NAFLD患者114例,將其隨機(jī)分為治療組和對照組,每組57例。治療組口服消癥散積Ⅰ號方,對照組口服復(fù)方左旋肉堿,均為每日口服一次,每次1.8g,連續(xù)治療12周。觀察兩組患者治療前后體重、肝功能、血脂、胰島素抵抗指數(shù)(HOMA-IR)等指標(biāo)的變化,并比較兩組療效和安全性。

結(jié)果:治療組患者治療后體重、甘油三酯(TG)、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)及HOMA-IR指數(shù)均顯著下降,高密度脂蛋白膽固醇(HDL-C)升高,且與對照組比較差異有統(tǒng)計(jì)學(xué)意義(均P<0.05)。治療組患者的總有效率為89.47%,對照組為75.44%,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組患者均未出現(xiàn)不良反應(yīng)。

結(jié)論:消癥散積Ⅰ號方治療濕郁血瘀型NAFLD具有較好的療效和安全性,值得臨床推廣應(yīng)用。

關(guān)鍵詞:消癥散積Ⅰ號方;非酒精性脂肪性肝??;濕郁血瘀型;療效;安全性

Abstract:

Objective:ToinvestigatetheclinicalefficacyandsafetyofXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypenonalcoholicfattyliverdisease(NAFLD).

Methods:Atotalof114NAFLDpatientswhowerehospitalizedfortreatmentfromJanuary2017toDecember2019wererandomlydividedintoatreatmentgroupandacontrolgroup,with57casesineachgroup.ThetreatmentgroupwasgivenXiaozhenSanjiIformula,andthecontrolgroupwasgivenlevocarnitine,bothofwhichweretakenorallyonceadayatadoseof1.8geachtimefor12consecutiveweeks.Thechangesinweight,liverfunction,bloodlipids,andinsulinresistanceindex(HOMA-IR)beforeandaftertreatmentwereobservedinbothgroups,andtheefficacyandsafetyofbothgroupswerecompared.

Results:Aftertreatment,theweight,triglycerides(TG),totalcholesterol(TC),low-densitylipoproteincholesterol(LDL-C),andHOMA-IRindexinthetreatmentgroupweresignificantlydecreased,andhigh-densitylipoproteincholesterol(HDL-C)wassignificantlyincreased,andthedifferencescomparedwiththecontrolgroupwerestatisticallysignificant(P<0.05).Thetotaleffectiverateofthetreatmentgroupwas89.47%,whichwassignificantlyhigherthanthatofthecontrolgroup(75.44%,P<0.05).Noadversereactionswereobservedinbothgroups.

Conclusion:XiaozhenSanjiIformulahasgoodefficacyandsafetyinthetreatmentofdampnessstagnationandbloodstasistypeNAFLD,andisworthyofclinicalpromotionandapplication.

Keywords:XiaozhenSanjiIformula;nonalcoholicfattyliverdisease;dampnessstagnationandbloodstasistype;efficacy;safet。Nonalcoholicfattyliverdisease(NAFLD)hasbecomeamajorpublichealthissueworldwide,anditsprevalenceisincreasing.ItisimportanttofindeffectiveandsafetreatmentoptionsforNAFLD,especiallyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.Inthisstudy,weevaluatedtheefficacyandsafetyoftheXiaozhenSanjiIformulaforthetreatmentofthistypeofNAFLD.

OurresultsshowedthattheXiaozhenSanjiIformulahadasignificanteffectonimprovingtheliverfunction,lipidmetabolism,andinflammationinpatientswithdampnessstagnationandbloodstasistypeNAFLD.After12weeksoftreatment,thetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).

TheXiaozhenSanjiIformulaisatraditionalChineseherbalmedicineformulathathasbeenusedformanyyearsinChinatotreatliverdiseases.Itconsistsofseveralherbs,includingRadixPaeoniaeAlba,SemenPersicae,andRhizomaAtractylodisMacrocephalae,whichhavebeenshowntohavepharmacologicaleffectsontheliver,lipidmetabolism,andinflammation.

Ourstudyhassomelimitations,includingasmallsamplesizeandashortfollow-upperiod.Therefore,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtoconfirmtheefficacyandsafetyoftheXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypeNAFLD.

Inconclusion,ourstudysuggeststhattheXiaozhenSanjiIformulaisaneffectiveandsafetreatmentoptionforpatientswithdampnessstagnationandbloodstasistypeNAFLD.IthasthepotentialtobewidelyusedinclinicalpracticeasacomplementarytherapyforNAFLD。Non-alcoholicfattyliverdisease(NAFLD)hasbecomeaglobalhealthconcernduetotheincreasingprevalenceandpotentialliver-relatedcomplicationsassociatedwiththecondition.ThetraditionalChinesemedicine(TCM)formulaXiaozhenSanjiIhasbeenusedtotreatNAFLDinChina,buttheefficacyandsafetyoftheformulahavenotbeenwidelystudied.

Basedontheavailableevidence,itcanbeconcludedthatXiaozhenSanjiIisaneffectiveandsafetherapyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.TheformulahasthepotentialtobecomeanimportantcomplementarytherapyinthemanagementofNAFLD,especiallyforpatientswhodonotrespondwelltoconventionaltreatmentoptions.

However,morestudieswithlargersamplesizesandlongerfollow-upperiodsareneededtofullyunderstandtheefficacyandsafetyofXiaozhenSanjiI.Additionally,futurestudiesshouldalsofocusontheunderlyingmechanismsofactionoftheformulaandtheoptimaldosageanddurationoftreatment.

Overall,TCMformulassuchasXiaozhenSanjiIofferapromisingalternativetoconventionaltreatmentsforNAFLD.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMformulas,othertraditionaltherapiessuchasacupunctureandmoxibustionhavealsoshownpromiseinthetreatmentofNAFLD.Thesetherapieshavebeenfoundtoimproveliverfunction,reduceinflammation,andincreaseinsulinsensitivity,amongotherbenefits.

Acupunctureinvolvestheinsertionoffineneedlesintospecificpointsonthebodytostimulatehealingandimprovefunction.Studieshaveshownthatacupuncturecanreduceliverenzymes,improveinsulinsensitivity,andreduceinflammationinpatientswithNAFLD.Moxibustion,whichinvolvestheburningoftheherbmugwortonspecificacupuncturepoints,hasalsobeenfoundtoimproveliverfunctionandreduceinflammation.

Combinedwithlifestylemodificationssuchasdietarychanges,exercise,andstressreduction,TCMtherapiesandtraditionaltherapieslikeacupunctureandmoxibustioncanprovideacomprehensiveapproachtothetreatmentofNAFLD.Thisintegratedapproachcanimproveliverfunction,reduceinflammation,andimproveoverallhealthoutcomesforpatientswithNAFLD.

Inconclusion,theincreasingprevalenceofNAFLDrepresentsasignificanthealthchallengeworldwide.Whileconventionaltreatmentsfocusprimarilyonlifestylemodificationsandmedicationstocontrolsymptoms,TCMtherapiesofferapromisingalternativeforpatientswithNAFLD.VariousTCMformulasandtraditionaltherapieslikeacupunctureandmoxibustionhavebeenshowntoimproveliverfunction,reduceinflammation,andprovideotherbenefits.Futureresearchshouldcontinuetoexploretheefficacyandunderlyingmechanismsofthesetherapies,aswellasoptimaldosageanddurationoftreatment.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMtherapies,lifestylechangesplayacrucialroleinthemanagementofNAFLD.Obesity,insulinresistance,andhighbloodpressureareallassociatedwithanincreasedriskofdevelopingNAFLD,andaddressingtheseunderlyingconditionscanimproveliverhealth.Weightloss,throughacombinationofdietandexercise,hasbeenshowntoimproveliverfunctionandreduceinflammationinpatientswithNAFLD.Alow-carbohydrate,high-proteindiethasbeenfoundtobeparticularlyeffective,asitstabilizesbloodsugarlevelsandpromotesfatburning.

RegularphysicalactivityisalsoimportantinthemanagementofNAFLD,asitimprovesinsulinsensitivityandpromotesweightloss.ForpatientswithNAFLD,acombinationofbothaerobicandresistancetrainingisrecommended.Exercisehasbeenshowntoimproveliverfunction,reduceinflammation,andimproveoverallqualityoflifeinpatientswithNAFLD.

Inconclusion,NAFLDisacomplexandmultifactorialdiseasethatrequiresaholisticapproachtomanagement.TheincorporationofTCMtherapies,suchasacupunctureandmoxibustion,intoconventionaltreatmentplanscanprovidepatientsw

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論